Real-world outcomes of robotic and non-robotic hysterectomy for endometrial cancer: insights from a national cohort Authors: Hui-Hsuan Lau, Yu-san Chien, Jiun-Yi Li, Ching-Hu Chung Published: 2025 ABSTRACT To compare perioperative outcomes, postoperative complications, and overall survival among patients with endometrial cancer (EC) undergoing open hysterectomy (OH), laparoscopic hysterectomy (LH), or robot-assisted hysterectomy (RAH) using nationwide real-world data. This was a retrospective, population-based study using 2018–2020 Taiwan Cancer Registry who underwent one of three surgical approaches (open, laparoscopic, or robot-assisted) and outcomes were evaluated using NHIRD with follow-up data available through 2021. From these linked datasets, we identified 5,360 women diagnosed with endometrial cancer who received hysterectomy, including 3,176 cases of OH, 1,760 LH, and 424 RAH. Inverse probability weighting (IPTW) methodology was utilized to harmonize baseline characteristics across the study arms. Compared with OH, RAH was associated with significantly fewer transfusions (15.5% vs. 29.7% (p < 0.0001)), shorter hospital stays (5.9 vs. 8.0 days, p < 0.0001), and reduced intensive care utilization. At one month postoperatively, overall complication rates were markedly lower in the RAH group (0.95%) than in OH (7.52%) and LH (6.07%) (both p < 0.0001). Specific complications, including vascular events, cardiac events, stroke, pneumonia, peritonitis, and wound disruption, were significantly reduced with RAH. Mortality analysis showed that OH was shown higher mortality hazard ratios compared with RAH (HR 1.39, 95% CI: 1.20–1.61 after IPTW), while survival outcomes were similar between RAH and LH (HR 0.97, 95% CI: 0.73–1.28). RAH for endometrial cancer demonstrated significant perioperative and postoperative advantages compared with OH, including lower complication rates and improved survival outcomes. RAH outcomes were largely comparable to laparoscopic hysterectomy. These findings support broader consideration of RAH as a safe and effective minimally invasive approach for EC management in real-world practice, although further long-term evaluation is warranted. Introduction Endometrial cancer (EC) originates from the mucosal layer of the uterus and is recognized as one of the most common malignancies affecting the female reproductive system. Globally, around 417,000 new diagnoses were recorded in 2020, ranking EC as the sixth leading cancer among women [1]. Although EC can develop across a broad age range, it primarily affects women after menopause. Approximately 3% of women are expected to develop endometrial cancer during their lifetime, and the median age at diagnosis is around 61 [1]. Over the last three decades, its global incidence has escalated by nearly 132%, mainly due to the growing prevalence of obesity and population aging trends [2]. Management strategies for endometrial cancer are largely determined by disease stage, patient comorbidities, and tumor-specific features. The primary treatment is surgery, but it may be supplemented with other therapies such as radiation, chemotherapy, and hormone therapy, especially in advanced or high-risk cases [3]. In recent years, the use of minimally invasive techniques for managing EC has shown a continuous upward trend [4, 5]. Among these, robot-assisted surgery (RAS) has been increasingly adopted due to its technical benefits, such as three-dimensional visualization, enhanced instrument dexterity, and reduced dependence on an experienced surgical team. Current evidence generally indicates that short-term complication rates are comparable between RAS and conventional laparoscopic surgery in EC patients [6]. In a post-hoc analysis, Melamed et al. found that the decline in survival reached statistical significance only within the RAS group, while the hazard ratio for the laparoscopic arm crossed unity, suggesting that the two minimally invasive techniques may not yield identical outcomes [7]. Although our study focuses on endometrial cancer, we referenced Melamed et al.‘s large-scale cohort analysis on cervical cancer to highlight that robot-assisted or minimally invasive techniques may not universally confer survival benefits across all gynecologic malignancies. Their findings underscore the importance of evaluating oncologic outcomes beyond perioperative advantages, particularly in robot-assisted approaches. Multiple investigations have shown that RAH for endometrial cancer tends to yield superior perioperative outcomes when compared with conventional surgical methods [6, 8]. However, real-world comparative data examining RAH, LH, and OH in the Taiwanese clinical setting remain limited. This nationwide retrospective analysis sought to compare oncologic outcomes and postoperative morbidity among patients with endometrial cancer treated by RAH, LH, or OH in real-world clinical settings. Methods Data source and patient definition This was a retrospective, population-based study using 2018–2020 Taiwan Cancer Registry who underwent one of three surgical approaches (open, laparoscopic, or robot-assisted) and outcomes were evaluated using NHIRD with follow-up data available through 2021. The linkage between the Taiwan Cancer Registry and the NHIRD was established using encrypted National identification numbers, which serve as unique identifiers across all healthcare encounters in Taiwan. This linkage achieved a match rate of 98.7%, with unmatched cases primarily due to death, migration, or data entry errors. The NHIRD captures all deaths through integration with the national death registry and records all healthcare events across hospitals, ensuring nearly complete follow-up. This population-based linkage design minimizes selection bias, enables comprehensive tracking of outcomes, and provides robust data validity for evaluating real-world surgical effectiveness and safety. Patients with histologically confirmed endometrial carcinoma (ICD-O-3 code C54.1) and their primary surgical approach were first identified from the Taiwan Cancer Registry, which provides precise topographic and morphological classification. Subsequent information on surgical timing, hospitalization, perioperative complications, transfusion, and readmission was obtained from the NHIRD using ICD-10 clinical codes (C54.1 for malignant neoplasm of the endometrium). This combined use of ICD-O-3 for accurate cancer identification and ICD-10 for outcome verification ensured both diagnostic precision and comprehensive follow-up in the analysis. During the study period (2018–2020), RAH was available as a self-pay procedure in Taiwan, prior to receiving formal National Health Insurance reimbursement approval in September 2024. The use of the Taiwan Cancer Registry as the diagnostic criterion for EC is both stringent and reliable. Information on surgery type (OH, LH or RAH), cancer stage, tumor size (mm), lymphovascular invasion, and smoking status was obtained by linking with the Taiwan Cancer Registry. Ethical approval Approval for the study was granted by the Institutional Review Board of MacKay Memorial Hospital (Taiwan; approval number 22MMHIS360e). Because this was a retrospective data-based study, the requirement for obtaining informed consent was formally waived. Assessment Comorbid conditions in patients with EC were determined using the Charlson Comorbidity Index (CCI), with coding adapted according to reference [9]. The study compared survival distributions of the three surgical modalities using Kaplan–Meier estimation, with the log-rank test applied to assess statistical differences. Overall survival was defined as the interval extending from surgical intervention to death from any cause. To account for baseline imbalances and multiple confounders among the three surgical groups, we applied inverse probability of treatment weighting (IPTW) using propensity scores estimated via multinomial logistic regression. Covariates included age, Charlson Comorbidity Index, cancer stage, body mass index, smoking status, tumor size, lymphovascular invasion, and receipt of neoadjuvant therapy. This approach creates a weighted pseudo-population in which these factors are evenly distributed across treatment arms, thereby mitigating selection bias arising from differences in patient complexity and institutional capability. By balancing these covariates, IPTW reduces the influence of confounding variables that could otherwise worsen observed clinical outcomes in older or more advanced cases predominantly treated with OH. Additionally, inclusion of surgery year and hospital level in the propensity model partially adjusted for temporal adoption effects, since RAH was primarily performed later in the study period at tertiary centers by experienced gynecologic oncologists. After weighting, all standardized mean differences were < 0.1, indicating adequate balance among groups and supporting the validity of comparative outcome estimates. Total medical costs were calculated using reimbursement data from the NHIRD, encompassing all inpatient and outpatient expenses related to the index surgery and follow-up. These included operating room time, anesthesia, surgical and medical equipment, physician and nursing fees, medications, transfusions, ward charges, intensive care, and any subsequent readmissions. This approach captures both procedural and hospitalization-related costs, providing a comprehensive estimate of healthcare expenditures under Taiwan’s National Health Insurance system. Statistics Data analysis included descriptive, survival, and regression components. Categorical parameters were summarized as frequencies and percentages, whereas continuous variables were expressed as mean (SD) or median (IQR). Kaplan–Meier plots with log-rank tests assessed survival disparities between surgical strategies, with overall survival defined as the time from surgery to death. To evaluate differences in postoperative outcomes, logistic regression produced odds ratios (ORs) with 95% confidence intervals (CIs). Analyses were performed using both the crude dataset and the IPTW-adjusted cohort to control for confounders. Two-tailed p-values < 0.05 were considered significant. Results Sample description From 2018 to 2021, the NHIRD identified 3,176 OH, 424 RAH, and 1,760 LH cases (Fig. 1). Mean ages were 56.74 ± 10.83 (OH), 55.34 ± 10.60 (RAH), and 56.06 ± 10.86 (LH), with most patients aged 50–69 years (Table 1). CCI ≥ 3 showed no group difference. Late-stage disease (stage 3–4) was more frequent in OH (13.28%) than LH (2.84%) or RAH (2.83%, p < 0.0001). Tumor sizes were larger in OH (47.58 ± 31.73 mm) than LH (30.26 ± 19.98 mm³) and RAH (32.52 ± 20.08 mm³). After IPTW, baseline characteristics were balanced (Table 2). Fig. 1enrollment flow enrollment flow Table 1Demographic data (OH (N = 3,176), RAH (N = 424), LH (N = 1,760))OH (N = 3176)RAH (N = 424)LH (N = 1760)P-valueSMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/LHRAH/LHOH/RAHOH/LHRAH/LHAge56.74(10.83)56.50(14)55.34(10.60)56(13)56.06(10.86)56(14)0.01220.03640.2141−0.130780.063−0.06774Age Group18 to < 5076223.99%11527.12%44125.06%0.15840.40410.38070.07176−0.01240.0470250 to < 70205064.55%27063.68%113764.60%0.7260.96880.7216−0.01807−0.0005−0.0192370+36411.46%399.20%18210.34%0.16510.22950.4836−0.074360.018−0.03847BMI26.66(5.55)25.70(7.10)26.55(5.82)25.20(6.80)26.59(5.51)25(7.10)0.69720.6590.8930.0190.013−0.007Normal108634.19%16037.74%64936.88%0.14990.05880.74180.07381−0.02810.01779Overweight205864.00%25159.20%109862.39%0.02390.09090.2252−0.115490.0167−0.06529NA321.01%133.07%130.74%0.00030.341< 0.00010.14598−0.17660.17082Charlson Comorbidity Index0–185726.98%10625.00%48127.33%0.38610.79340.3314−0.04521−0.0039−0.052982138543.61%20748.82%79044.89%0.04240.38630.14430.10462−0.01290.078853+93429.41%11126.18%48927.78%0.16890.22760.5063−0.072070.018−0.03614Cancer stage (CTNM)1240675.76%38290.09%163292.73%< 0.0001< 0.00010.06930.38797−0.02466−0.09399234810.96%307.08%784.43%0.0143< 0.00010.0242−0.135760.1260.11362338512.12%122.83%502.84%< 0.0001< 0.00010.8795−0.37102−0.1913−0.008254371.16%0.0787< 0.00010.5419−0.11155−0.19130.02924Neoadjuvant therapyYes842.64%71.65%351.99%0.22070.150.6495−0.068560.0217−0.02525No309297.36%41798.35%172598.01%0.22070.150.6495−0.06856−0.0217−0.02525Tumor size(mm)47.58(31.73)40(36)32.52(20.08)30(27)30.26(19.98)26(24)< 0.0001< 0.00010.04710.026890.651−0.20356LateralityLymph vascular invasion104532.90%11426.89%34819.77%0.0128< 0.00010.0013−0.131620.15120.16868Smoking1253.94%112.59%623.52%0.17360.46660.3397−0.075490.0111−0.0539OperationPelvic lymphadenectomy1675.2615< 0.0001< 0.00010.2104−0.31090.26268−0.07815Laparoscopic pelvic lymphadenectomy000000Paraaortic lymphadenectomy481.5100181.020.01080.15230.0365−0.175160.04369−0.14372Laparoscopic paraaortic lymphadenectomy000000Hospital levelMedical center159750.2825259.43111363.24< 0.00010.003< 0.00011.610622.001320.23837Other105552417240.5660034.09< 0.00010.003< 0.00011.610622.001320.23837Missing52416.5472.67< 0.00010.003< 0.00011.610622.001320.23837SpecialtyObstetrics and Gynecology262582.6542299.53170296.7< 0.00010.0214< 0.00011.575921.943750.20672Others270.85110.63< 0.00010.0214< 0.00011.575921.943750.20672Missing52416.520.47472.67< 0.00010.0214< 0.00011.575921.943750.20672 Table 1Demographic data (OH (N = 3,176), RAH (N = 424), LH (N = 1,760))OH (N = 3176)RAH (N = 424)LH (N = 1760)P-valueSMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/LHRAH/LHOH/RAHOH/LHRAH/LHAge56.74(10.83)56.50(14)55.34(10.60)56(13)56.06(10.86)56(14)0.01220.03640.2141−0.130780.063−0.06774Age Group18 to < 5076223.99%11527.12%44125.06%0.15840.40410.38070.07176−0.01240.0470250 to < 70205064.55%27063.68%113764.60%0.7260.96880.7216−0.01807−0.0005−0.0192370+36411.46%399.20%18210.34%0.16510.22950.4836−0.074360.018−0.03847BMI26.66(5.55)25.70(7.10)26.55(5.82)25.20(6.80)26.59(5.51)25(7.10)0.69720.6590.8930.0190.013−0.007Normal108634.19%16037.74%64936.88%0.14990.05880.74180.07381−0.02810.01779Overweight205864.00%25159.20%109862.39%0.02390.09090.2252−0.115490.0167−0.06529NA321.01%133.07%130.74%0.00030.341< 0.00010.14598−0.17660.17082Charlson Comorbidity Index0–185726.98%10625.00%48127.33%0.38610.79340.3314−0.04521−0.0039−0.052982138543.61%20748.82%79044.89%0.04240.38630.14430.10462−0.01290.078853+93429.41%11126.18%48927.78%0.16890.22760.5063−0.072070.018−0.03614Cancer stage (CTNM)1240675.76%38290.09%163292.73%< 0.0001< 0.00010.06930.38797−0.02466−0.09399234810.96%307.08%784.43%0.0143< 0.00010.0242−0.135760.1260.11362338512.12%122.83%502.84%< 0.0001< 0.00010.8795−0.37102−0.1913−0.008254371.16%0.0787< 0.00010.5419−0.11155−0.19130.02924Neoadjuvant therapyYes842.64%71.65%351.99%0.22070.150.6495−0.068560.0217−0.02525No309297.36%41798.35%172598.01%0.22070.150.6495−0.06856−0.0217−0.02525Tumor size(mm)47.58(31.73)40(36)32.52(20.08)30(27)30.26(19.98)26(24)< 0.0001< 0.00010.04710.026890.651−0.20356LateralityLymph vascular invasion104532.90%11426.89%34819.77%0.0128< 0.00010.0013−0.131620.15120.16868Smoking1253.94%112.59%623.52%0.17360.46660.3397−0.075490.0111−0.0539OperationPelvic lymphadenectomy1675.2615< 0.0001< 0.00010.2104−0.31090.26268−0.07815Laparoscopic pelvic lymphadenectomy000000Paraaortic lymphadenectomy481.5100181.020.01080.15230.0365−0.175160.04369−0.14372Laparoscopic paraaortic lymphadenectomy000000Hospital levelMedical center159750.2825259.43111363.24< 0.00010.003< 0.00011.610622.001320.23837Other105552417240.5660034.09< 0.00010.003< 0.00011.610622.001320.23837Missing52416.5472.67< 0.00010.003< 0.00011.610622.001320.23837SpecialtyObstetrics and Gynecology262582.6542299.53170296.7< 0.00010.0214< 0.00011.575921.943750.20672Others270.85110.63< 0.00010.0214< 0.00011.575921.943750.20672Missing52416.520.47472.67< 0.00010.0214< 0.00011.575921.943750.20672 Demographic data (OH (N = 3,176), RAH (N = 424), LH (N = 1,760)) Perioperative outcomes Before IPTW, transfusion rates were 30.32% (OH), 13.92% (RAH), and 11.93% (LH) (p < 0.0001) (Table 3). Mean hospital stay was 8.09 days (OH), 5.99 (RAH), and 5.44 (LH) (p < 0.0001). ICU admission rates were 3.94% (OH), 2.12% (RAH), and 1.48% (LH). Reoperation rates were 0.98% (OH), 4.72% (RAH), and 3.01% (LH); readmissions were 3.31%, 6.37%, and 4.72%, respectively (both p < 0.01). Costs were NTD 130,281 (OH), 65,992 (RAH), and 121,001 (LH) (all p < 0.0001), with consistent savings across 30-, 60-, 90-day, and 12-month follow-ups. After IPTW, transfusion remained lower in RAH (15.51%) vs. OH (29.67%, p < 0.0001); LH was not different from RAH. Mean stay was 8.05 (OH), 5.90 (RAH), and 5.45 (LH) days (p < 0.0001). ICU days were shorter in RAH vs. OH (p = 0.0097). Reoperation was higher in RAH (3.86%) vs. OH (1.01%, p < 0.0001) and in LH (4.19%) vs. RAH (3.07%, p = 0.0489). Costs favored RAH and LH over OH across all time points (p < 0.0001). Age GroupTable 2IPTW_Demographic data (A) OH vs. RAH; (B) RAH vs. LH AOH (N = 3600)RAH (N = 3583)P-valueSMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/RAHAge56.58(11.52)56(14)57.16(32.03)57.00(12)0.30280.05482Age Group18 to < 50 87724.36%81022.60%0.0773−0.040550 to < 70 232064.44%235065.60%0.30370.0241270+40311.20%42311.81%0.41870.02001BMI26.64(5.92)25.60(7.20)26.73(17.32)25.40(7.20)0.7697−0.007Normal124734.63%131436.67%0.07190.04239Overweight230964.13%223162.28%0.1039−0.03834NA441.24%381.06%0.4863−0.01241Charlson Comorbidity Index0–196326.74%97427.18%0.67850.009892159244.23%161345.04%0.49020.016253+104529.03%99627.79%0.2426−0.02776Cancer stage (CTNM)1278877.45%280578.28%0.39540.02253237810.50%3449.60%0.2045−0.03149339611.00%40811.40%0.59220.015524381.06%260.72%0.1354−0.03973Neoadjuvant therapyYes912.53%631.75%0.0233−0.05342No350997.47%352098.25%0.0233−0.05342Tumor size(mm)46.99(33.32)40(35)35.13(63.58)30(30)<.00010.01446LateralityLymph vascular invasion116032.22%116432.48%0.81330.0057Smoking1363.78%1754.88%0.02170.06207OperationPelvic lymphadenectomy1855.1490.24<.0001Laparoscopic pelvic lymphadenectomy0000Paraaortic lymphadenectomy541.4900<.0001Laparoscopic paraaortic lymphadenectomy0000Hospital levelMedical center182050.56198355.34<.0001Other178049.44160044.66<.0001SpecialtyObstetrics and Gynecology299883.27355699.24<.0001Others60216.73270.76<.0001BLH (N = 2185) RAH (N = 2168) P-value SMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/RAHAge55.90(12.18)56(14)55.86(24.17)56(13)0.9529−0.0032Age Group18 to < 50 55925.56%56125.88%0.8070.0073750 to < 70 140564.31%138463.82%0.7344−0.0102870+22110.13%22310.30%0.85330.00571BMI26.55(6.11)25.60(7.20)26.60(13.11)25.30(6.70)0.8791−0.005Normal80837.01%81037.36%0.8080.00735Overweight134961.73%133161.40%0.8248−0.00669NA281.27%271.24%0.9308−0.00216Charlson Comorbidity Index0–158626.82%58026.74%0.9473−0.01887299945.71%100246.24%0.7258−0.002023+60027.47%58627.03%0.74380.01062Cancer stage (CTNM)1201592.21%199091.76%0.58720.0148221084.94%1145.29%0.60570.004523622.85%642.96%0.8830.007014381.06%260.72%0.8097−0.00993Neoadjuvant therapyYes441.99%211997.74%0.54480.01978No214198.01%492.26%0.54480.01978Tumor size(mm)30.62(22.65)27(24)31.53(44.39)30(25)0.4209−0.0651LateralityLymph vascular invasion46521.27%46621.51%0.84650.0057Smoking733.35%773.53%0.73950.01066OperationPelvic lymphadenectomy170.840.170.0026Laparoscopic pelvic lymphadenectomy0000paraaortic lymphadenectomy221.0300<.0001Laparoscopic paraaortic lymphadenectomy0000Hospital levelMedical center138263.23130059.97<.0001Other80336.7786840.03<.0001SpecialtyObstetrics and Gynecology211296.64215199.19<.0001Others733.34170.81<.0001Table 3Perioperative outcomesUnmatched groupIPTWOH (N = 3176)RAH (N = 424)LH (N = 1760)OH/RAHOH/LHRAH/LHOH (N = 3600)RAH (N = 3583)P-valueLH (N = 2185)RAH (N = 2168)P-valueTransfusion (Y/N)N,%963,30.32%59,13.92%210,11.93%< 0.0001< 0.00010.26461068,29.67%556,15.51%< 0.0001267,12.22%289,13.31%0.2818Length of Stay (day)Mean (Std)8.09(5.97)5.99(3.98)5.44(3.31)< 0.0001< 0.00010.00818.05(6.23)5.90(11.80)< 0.00015.45(3.72)6.06(9.03)< 0.0001ICU stay (day)N,%125,3.94%9,2.12%26,1.48%0.064< 0.00010.3421134,3.73%106, 2.96%0.616339,1.51%48,2.20%0.089Mean (Std)2.56(2.31)1.67(0.71)2.32(1.77)0.00880.4940.36332.55(2.40)1.79(2.44)0.00972.22(1.99)1.71(1.54)0.2397Follow-up time (day)Mean (Std)808.1(346.1)889.8.(344.4)826.1(318.4)< 0.00010.0650.0006811.7(366.7)879.6(1019.6)< 0.0001826.4(354.6)897.6(779.2)0.0001ReoperationN,%31,0.98%20,4.72%53,3.01%< 0.0001< 0.00010.079436,1.01%138,3.86%< 0.000167,3.07%91,4.19%0.0489ReadmissionN,%105,3.31%27,6.37%83,4.72%0.00160.01320.1626119,3.32%192,5.34%< 0.0001105,4.79%116,5.37%0.386Total Medical CostIn-hospital Mean (SD)130,281(62077.9)65992.2(27333.9)121,001(32871.4)< 0.0001< 0.0001< 0.0001129,151(64578.1)67925.3(82609.7)< 0.0001121,214(36697.5)660301.9(61351.6)< 0.000130-day Mean (SD)136,147(71901.8)33956.3(1649.1)123,351(43350.8)< 0.0001< 0.0001< 0.0001134,943(75097.4)74544.2(101603)< 0.0001123,540(48611.9)70941.0(75041.5)< 0.000160-day Mean (SD)139,444(777283.5)72486.3(34172.5)124,629(44393.4)< 0.0001< 0.0001< 0.0001138,117(80558.8)75677.9(101846)< 0.0001124,839(49778.6)72260.9(75613.9)< 0.000190-day Mean (SD)141,557(81445.4)73129.9(34247.5)125,459(45777.4)< 0.0001< 0.0001< 0.0001140,173(84988.7)765455.0(101924)< 0.0001125,655(51285.8)72883.7(75843.1)< 0.000112 month Mean (SD)151,001(98790.3)77314.9(39292.2)131,557(60252.6)< 0.0001< 0.0001< 0.0001149,516(103780)80770.4(114676)< 0.0001131,609(67100.1)77252.5(87669.0)< 0.0001 Table 2IPTW_Demographic data (A) OH vs. RAH; (B) RAH vs. LH AOH (N = 3600)RAH (N = 3583)P-valueSMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/RAHAge56.58(11.52)56(14)57.16(32.03)57.00(12)0.30280.05482Age Group18 to < 50 87724.36%81022.60%0.0773−0.040550 to < 70 232064.44%235065.60%0.30370.0241270+40311.20%42311.81%0.41870.02001BMI26.64(5.92)25.60(7.20)26.73(17.32)25.40(7.20)0.7697−0.007Normal124734.63%131436.67%0.07190.04239Overweight230964.13%223162.28%0.1039−0.03834NA441.24%381.06%0.4863−0.01241Charlson Comorbidity Index0–196326.74%97427.18%0.67850.009892159244.23%161345.04%0.49020.016253+104529.03%99627.79%0.2426−0.02776Cancer stage (CTNM)1278877.45%280578.28%0.39540.02253237810.50%3449.60%0.2045−0.03149339611.00%40811.40%0.59220.015524381.06%260.72%0.1354−0.03973Neoadjuvant therapyYes912.53%631.75%0.0233−0.05342No350997.47%352098.25%0.0233−0.05342Tumor size(mm)46.99(33.32)40(35)35.13(63.58)30(30)<.00010.01446LateralityLymph vascular invasion116032.22%116432.48%0.81330.0057Smoking1363.78%1754.88%0.02170.06207OperationPelvic lymphadenectomy1855.1490.24<.0001Laparoscopic pelvic lymphadenectomy0000Paraaortic lymphadenectomy541.4900<.0001Laparoscopic paraaortic lymphadenectomy0000Hospital levelMedical center182050.56198355.34<.0001Other178049.44160044.66<.0001SpecialtyObstetrics and Gynecology299883.27355699.24<.0001Others60216.73270.76<.0001BLH (N = 2185) RAH (N = 2168) P-value SMDN or mean (SD)% or median (IQR)N or mean (SD)% or median (IQR)OH/RAHOH/RAHAge55.90(12.18)56(14)55.86(24.17)56(13)0.9529−0.0032Age Group18 to < 50 55925.56%56125.88%0.8070.0073750 to < 70 140564.31%138463.82%0.7344−0.0102870+22110.13%22310.30%0.85330.00571BMI26.55(6.11)25.60(7.20)26.60(13.11)25.30(6.70)0.8791−0.005Normal80837.01%81037.36%0.8080.00735Overweight134961.73%133161.40%0.8248−0.00669NA281.27%271.24%0.9308−0.00216Charlson Comorbidity Index0–158626.82%58026.74%0.9473−0.01887299945.71%100246.24%0.7258−0.002023+60027.47%58627.03%0.74380.01062Cancer stage (CTNM)1201592.21%199091.76%0.58720.0148221084.94%1145.29%0.60570.004523622.85%642.96%0.8830.007014381.06%260.72%0.8097−0.00993Neoadjuvant therapyYes441.99%211997.74%0.54480.01978No214198.01%492.26%0.54480.01978Tumor size(mm)30.62(22.65)27(24)31.53(44.39)30(25)0.4209−0.0651LateralityLymph vascular invasion46521.27%46621.51%0.84650.0057Smoking733.35%773.53%0.73950.01066OperationPelvic lymphadenectomy170.840.170.0026Laparoscopic pelvic lymphadenectomy0000paraaortic lymphadenectomy221.0300<.0001Laparoscopic paraaortic lymphadenectomy0000Hospital levelMedical center138263.23130059.97<.0001Other80336.7786840.03<.0001SpecialtyObstetrics and Gynecology211296.64215199.19<.0001Others733.34170.81<.0001 IPTW_Demographic data (A) OH vs. RAH; (B) RAH vs. LH Table 3Perioperative outcomesUnmatched groupIPTWOH (N = 3176)RAH (N = 424)LH (N = 1760)OH/RAHOH/LHRAH/LHOH (N = 3600)RAH (N = 3583)P-valueLH (N = 2185)RAH (N = 2168)P-valueTransfusion (Y/N)N,%963,30.32%59,13.92%210,11.93%< 0.0001< 0.00010.26461068,29.67%556,15.51%< 0.0001267,12.22%289,13.31%0.2818Length of Stay (day)Mean (Std)8.09(5.97)5.99(3.98)5.44(3.31)< 0.0001< 0.00010.00818.05(6.23)5.90(11.80)< 0.00015.45(3.72)6.06(9.03)< 0.0001ICU stay (day)N,%125,3.94%9,2.12%26,1.48%0.064< 0.00010.3421134,3.73%106, 2.96%0.616339,1.51%48,2.20%0.089Mean (Std)2.56(2.31)1.67(0.71)2.32(1.77)0.00880.4940.36332.55(2.40)1.79(2.44)0.00972.22(1.99)1.71(1.54)0.2397Follow-up time (day)Mean (Std)808.1(346.1)889.8.(344.4)826.1(318.4)< 0.00010.0650.0006811.7(366.7)879.6(1019.6)< 0.0001826.4(354.6)897.6(779.2)0.0001ReoperationN,%31,0.98%20,4.72%53,3.01%< 0.0001< 0.00010.079436,1.01%138,3.86%< 0.000167,3.07%91,4.19%0.0489ReadmissionN,%105,3.31%27,6.37%83,4.72%0.00160.01320.1626119,3.32%192,5.34%< 0.0001105,4.79%116,5.37%0.386Total Medical CostIn-hospital Mean (SD)130,281(62077.9)65992.2(27333.9)121,001(32871.4)< 0.0001< 0.0001< 0.0001129,151(64578.1)67925.3(82609.7)< 0.0001121,214(36697.5)660301.9(61351.6)< 0.000130-day Mean (SD)136,147(71901.8)33956.3(1649.1)123,351(43350.8)< 0.0001< 0.0001< 0.0001134,943(75097.4)74544.2(101603)< 0.0001123,540(48611.9)70941.0(75041.5)< 0.000160-day Mean (SD)139,444(777283.5)72486.3(34172.5)124,629(44393.4)< 0.0001< 0.0001< 0.0001138,117(80558.8)75677.9(101846)< 0.0001124,839(49778.6)72260.9(75613.9)< 0.000190-day Mean (SD)141,557(81445.4)73129.9(34247.5)125,459(45777.4)< 0.0001< 0.0001< 0.0001140,173(84988.7)765455.0(101924)< 0.0001125,655(51285.8)72883.7(75843.1)< 0.000112 month Mean (SD)151,001(98790.3)77314.9(39292.2)131,557(60252.6)< 0.0001< 0.0001< 0.0001149,516(103780)80770.4(114676)< 0.0001131,609(67100.1)77252.5(87669.0)< 0.0001 Perioperative outcomes Post-operative complications At 1 month, overall complication rates were 7.65% (OH), 0.94% (RAH), and 6.08% (LH) (p < 0.0001). ORs: RAH vs. OH 0.1150 (95% CI: 0.0426–0.3104, p < 0.001); RAH vs. LH 0.1471 (0.0539–0.4015, p < 0.001) (Table 4). RAH reduced vascular complications (OR 0.9843, 95% CI: 0.9779–0.9886, p = 0.0093), cardiac events (OR 0.9858, 95% CI: 0.9817–0.9900, p = 0.0136), and ileus (OR 0.9871, 95% CI: 0.9832–0.9910, p = 0.0186). After IPTW, complication rates remained lower: RAH 0.95%, OH 7.52%, LH 6.07% (both p < 0.0001). Adjusted ORs: RAH vs. OH 0.1176 (95% CI: 0.0820–0.1685, p < 0.001); RAH vs. LH 0.1401 (95% CI: 0.0867–0.2263, p < 0.001). Specific reductions with RAH vs. OH included vascular (OR 0.9844, p < 0.001), cardiac (0.9862, p < 0.001), stroke (0.9932, p < 0.001), pneumonia (0.9617, p < 0.001), acute renal failure (0.9982, p = 0.0103), peritonitis (0.9951, p < 0.001), ileus (0.9951, p < 0.001), genitourinary (0.5551, p = 0.0340), wound disruption (0.9957, p < 0.001), and surgical site infection (0.5257, p = 0.0468). Versus LH, RAH lowered sepsis (OR 0.9948, p = 0.0008), vascular (0.9909, p < 0.001), cardiac (0.9883, p < 0.001), stroke (0.9951, p = 0.0011), pneumonia (0.9947, p = 0.0007), peritonitis (0.9944, p = 0.0005), ileus (0.9950, p = 0.0009), and wound disruption (0.9972, p = 0.0134).Table 4Post-operative complication in one month after discharge form hospital for unmatching groupsAPost-operative complicationsOH (N =3176)RAH (N = 424)LH (N =1760)P-valueRAH/OHOH/LHRAH/LHNNNOH/RAHOH/LHRAH/LHOR95% CIOR95% CIOR95% CIAll243,7.65%4,0.94%107,6.08%<.00010.0394<.00010.1150.04260.31041.27991.01161.61940.14710.05390.4015Sepsis or disseminated intravascular coagulation8,0.25%09,0.51%0.30090.13610.14010.99750.99570.99920.49130.18921.27570.99490.99160.9982Pseudomembranous enterocolitis000Pulmonary embolism4,0.13%0180.46470.90540.48740.99870.997511.10840.20286.05780.99890.99731.0004Vascular complications50,1.57%00.00930.05130.04880.98430.97990.98861.74340.98993.07060.99090.98650.9954Cardiac events45,1.42%021,1.19%0.01360.51220.02380.98580.98170.991.19020.70672.00450.98810.9830.9932Stroke22,0.69%09,0.51%0.08560.43990.14010.99310.99020.9961.35710.62352.95370.99490.99160.9982Pneumonia or flu11,0.35%0140.22490.3820.14010.99650.99450.99860.67620.27971.63490.99490.99160.9982Respiratory complications900.52670.4630.39490.99910.9981.00010.55370.11162.74640.99830.99641.0002Acute renal failure00.37040.52880.48740.99810.99660.99961.66370.33548.25170.99890.99731.0004Peritonitis or peritoneal abscess16,0.50%010,0.57%0.1430.76460.11980.9950.99250.99740.88610.40121.95680.99430.99080.9978Ileus41,1.29%09,0.51%0.01860.00880.14010.98710.98320.9912.54441.23385.24750.99490.99160.9982Genitourinary complications32,1.01%415,0.85%0.28390.59050.42340.46560.11121.951.18410.63952.19250.55130.12562.4202Disruption of operation wound1780.17080.39440.27190.99560.99330.99791.55410.55884.32180.99720.99470.9996Other intraoperative complications0.52670.4630.39490.99910.9981.00010.55370.11162.74640.99830.99641.0002Surgical site infection24,0.76%10,0.57%0.51660.44560.80930.62240.14662.64311.33250.63572.79280.82940.18113.7993BPost-operative complicationsOPEN (N = 3600)RAS (N = 3583)P-valueOR95% CILAP (N = 2185)RAS (N =2168)P-valueOR95% CIAll271,7.52%34, 0.95%<.00010.11760.0820.1685133,6.07%19.4591,0.90%<.00010.14010.08670.2263Sepsis or disseminated intravascular coagulation9,0.24%00.00320.99760.9960.999211,0.52%00.00080.99480.99180.9978Pseudomembranous enterocolitis000Pulmonary embolism5,0.13%00.03340.99870.99760.99992,0.11%00.11560.99890.99741.0003Vascular complications56,1.56%0<.00010.98440.98030.988420,0.91%0<.00010.99090.9870.9949Cardiac events50,1.38%0<.00010.98620.98240.9926,1.17%0<.00010.98830.98380.9928Stroke25,0.68%0<.00010.99320.99050.995911,0.49%00.00110.99510.99220.998Pneumonia or flu138,3.83%0<.00010.96170.95550.96812,0.53%00.00070.99470.99170.9978Respiratory complications3,0.09%00.06710.99910.99811.00014,0.18%00.0510.99820.99651Acute renal failure7,0.18%00.01030.99820.99680.99963,0.12%00.10770.99880.99741.0003Peritonitis or peritoneal abscess18,0.49%0<.00010.99510.99280.997412,0.56%00.00050.99440.99120.9975Ileus46,1.27%0<.00010.98730.98360.990911,0.50%00.00090.9950.9920.9979Genitourinary complications36,0.99%20,0.55%0.0340.55510.31970.96419,0.86%9,0.41%0.06090.47310.21241.0536Disruption of operation wound15,0.43%0<.00010.99570.99360.99796,0.28%00.01340.99720.9950.9994Other intraoperative complications3,0.09%00.0740.99910.99811.00014,0.17%00.05630.99830.99661Surgical site infection27,0.75%14,0.40%0.04680.52570.27590.999413,0.61%11,0.49%0.6010.80590.35841.8123Patient numbers represent inverse probability treatment-weighted (IPTW) pseudo-populations to balance baseline covariates across groups Table 4Post-operative complication in one month after discharge form hospital for unmatching groupsAPost-operative complicationsOH (N =3176)RAH (N = 424)LH (N =1760)P-valueRAH/OHOH/LHRAH/LHNNNOH/RAHOH/LHRAH/LHOR95% CIOR95% CIOR95% CIAll243,7.65%4,0.94%107,6.08%<.00010.0394<.00010.1150.04260.31041.27991.01161.61940.14710.05390.4015Sepsis or disseminated intravascular coagulation8,0.25%09,0.51%0.30090.13610.14010.99750.99570.99920.49130.18921.27570.99490.99160.9982Pseudomembranous enterocolitis000Pulmonary embolism4,0.13%0180.46470.90540.48740.99870.997511.10840.20286.05780.99890.99731.0004Vascular complications50,1.57%00.00930.05130.04880.98430.97990.98861.74340.98993.07060.99090.98650.9954Cardiac events45,1.42%021,1.19%0.01360.51220.02380.98580.98170.991.19020.70672.00450.98810.9830.9932Stroke22,0.69%09,0.51%0.08560.43990.14010.99310.99020.9961.35710.62352.95370.99490.99160.9982Pneumonia or flu11,0.35%0140.22490.3820.14010.99650.99450.99860.67620.27971.63490.99490.99160.9982Respiratory complications900.52670.4630.39490.99910.9981.00010.55370.11162.74640.99830.99641.0002Acute renal failure00.37040.52880.48740.99810.99660.99961.66370.33548.25170.99890.99731.0004Peritonitis or peritoneal abscess16,0.50%010,0.57%0.1430.76460.11980.9950.99250.99740.88610.40121.95680.99430.99080.9978Ileus41,1.29%09,0.51%0.01860.00880.14010.98710.98320.9912.54441.23385.24750.99490.99160.9982Genitourinary complications32,1.01%415,0.85%0.28390.59050.42340.46560.11121.951.18410.63952.19250.55130.12562.4202Disruption of operation wound1780.17080.39440.27190.99560.99330.99791.55410.55884.32180.99720.99470.9996Other intraoperative complications0.52670.4630.39490.99910.9981.00010.55370.11162.74640.99830.99641.0002Surgical site infection24,0.76%10,0.57%0.51660.44560.80930.62240.14662.64311.33250.63572.79280.82940.18113.7993BPost-operative complicationsOPEN (N = 3600)RAS (N = 3583)P-valueOR95% CILAP (N = 2185)RAS (N =2168)P-valueOR95% CIAll271,7.52%34, 0.95%<.00010.11760.0820.1685133,6.07%19.4591,0.90%<.00010.14010.08670.2263Sepsis or disseminated intravascular coagulation9,0.24%00.00320.99760.9960.999211,0.52%00.00080.99480.99180.9978Pseudomembranous enterocolitis000Pulmonary embolism5,0.13%00.03340.99870.99760.99992,0.11%00.11560.99890.99741.0003Vascular complications56,1.56%0<.00010.98440.98030.988420,0.91%0<.00010.99090.9870.9949Cardiac events50,1.38%0<.00010.98620.98240.9926,1.17%0<.00010.98830.98380.9928Stroke25,0.68%0<.00010.99320.99050.995911,0.49%00.00110.99510.99220.998Pneumonia or flu138,3.83%0<.00010.96170.95550.96812,0.53%00.00070.99470.99170.9978Respiratory complications3,0.09%00.06710.99910.99811.00014,0.18%00.0510.99820.99651Acute renal failure7,0.18%00.01030.99820.99680.99963,0.12%00.10770.99880.99741.0003Peritonitis or peritoneal abscess18,0.49%0<.00010.99510.99280.997412,0.56%00.00050.99440.99120.9975Ileus46,1.27%0<.00010.98730.98360.990911,0.50%00.00090.9950.9920.9979Genitourinary complications36,0.99%20,0.55%0.0340.55510.31970.96419,0.86%9,0.41%0.06090.47310.21241.0536Disruption of operation wound15,0.43%0<.00010.99570.99360.99796,0.28%00.01340.99720.9950.9994Other intraoperative complications3,0.09%00.0740.99910.99811.00014,0.17%00.05630.99830.99661Surgical site infection27,0.75%14,0.40%0.04680.52570.27590.999413,0.61%11,0.49%0.6010.80590.35841.8123Patient numbers represent inverse probability treatment-weighted (IPTW) pseudo-populations to balance baseline covariates across groups Post-operative complication in one month after discharge form hospital for unmatching groups Patient numbers represent inverse probability treatment-weighted (IPTW) pseudo-populations to balance baseline covariates across groups Clinical outcomes of patients who underwent hysterectomy All-cause mortality HRs: OH vs. RAH 2.53 (95% CI: 1.64–3.88); LH vs. RAH 0.83 (0.52–1.34) (Fig. 2A). After IPTW: OH vs. RAH 1.39 (1.20–1.61); LH vs. RAH 0.97 (0.73–1.28). Kaplan-Meier curves confirmed higher mortality for OH vs. RAH and similar survival between RAH and LH (p < 0.001) (Fig. 2B and C). Fig. 2The all-cause mortality of different surgeries in three years. (A) unmatching groups; (B) OH vs. RAH; (C) LH vs. RAH The all-cause mortality of different surgeries in three years. (A) unmatching groups; (B) OH vs. RAH; (C) LH vs. RAH Discussion To our knowledge, this study represents the first nationwide investigation in Taiwan comparing survival and postoperative outcomes between RAH and conventional OH. The predominance of OH (59.2%) in this cohort reflects real-world clinical and institutional factors. Patients undergoing open surgery generally presented with more advanced disease (stage III–IV), larger tumors, and higher rates of lymphovascular invasion, requiring extensive procedures such as debulking or omentectomy. They also exhibited greater medical complexity, with higher transfusion and ICU utilization rates. Furthermore, during 2018–2020, minimally invasive techniques were not universally available across Taiwan, and variations in surgeon experience and hospital resources further influenced the choice of surgical approach. Since RAH was only approved by the Taiwan Bureau of National Health Insurance in September 2024, clinical experience with this technique remains relatively limited. Nevertheless, utilizing data from a national database, our analysis revealed that RAH was linked to markedly reduced rates of blood transfusion and postoperative complications compared with OH surgery. A 2023 meta-analysis compared RAH, LH, and OH and confirmed that robotic surgery offers better overall survival and lower recurrence rates in EC patients, particularly in early to intermediate stages of the disease [9]. These advantages have made robotic surgery an increasingly preferred option for both patients and surgeons in managing EC. Some studies suggest that RAH does not compromise long-term survival compared to OH surgery [10, 11]. Using real-world NHIRD data, we observed that patients who underwent RAH exhibited lower all-cause mortality rates than those who had OH surgery (Fig. 2A and B). Further prospective or long-term evaluations of RAH outcomes are warranted. RAH has demonstrated advantages over laparotomic (open) hysterectomy, particularly in reducing short-term complication rates, as observed in previous studies [12]. RAH is often favored over OH surgery when patient-specific factors favor minimally invasive techniques. These factors often apply to patients presenting with challenging surgical conditions, such as severe endometriosis, dense pelvic adhesions, obesity, advanced age, or multiple coexisting illnesses [13]. In their cohort of 152 women treated with RAH for technically demanding benign disorders—such as endometriosis, uterine leiomyoma, and previous pelvic or abdominal procedures—Boggess and co-authors found very few complications during or after surgery and reported no cases requiring laparotomic conversion [14]. Consistent with those findings, our analysis also demonstrated that RAH was linked to a significantly lower incidence of complications, as summarized in Tables 3 and 4. Patients undergoing RAH experience significantly less blood loss, averaging around 87.5 mL, compared to much higher blood loss in OH surgeries. This reduction is largely due to the precision of robotic instruments, which leads to fewer vascular injuries during surgery [15]. The length of hospital stay (LOS) in our cohort was longer than that reported in Western literature (1.8 days), primarily reflecting characteristics of Taiwan’s healthcare system and cultural recovery practices. Under the National Health Insurance program, hospitalization costs are low and comprehensive, encouraging prolonged inpatient recovery. Patients and families often prefer extended stays for perceived safety, while limited home care infrastructure and additional inpatient consultations for cancer management further contribute to longer LOS. Nevertheless, the relative reduction of approximately 27% in LOS for robotic-assisted hysterectomy compared with open hysterectomy is consistent with other Asian studies, underscoring the procedural advantages of minimally invasive approaches within the Taiwanese healthcare setting [16]. ICU admissions for robotic surgery patients are rare due to the minimally invasive nature of the procedure, which results in fewer complications. In contrast, OH surgery patients are more likely to require intensive care postoperatively, especially when significant blood loss or complications occurred [15]. According to our results, RAH demonstrated significantly lower transfusion rates compared to open surgery, both before and after IPTW adjustment. Conversely, there was no significant difference in transfusion rates between RAS and laparoscopic surgery in hysterectomy. This highlights the potential benefits of minimally invasive techniques such as RAS in reducing complications like transfusions and potentially shortening hospital stays for patients with EC undergoing hysterectomy. In Taiwan, RAH was performed as a self-pay procedure during the study period, so the NHIRD captured only hospitalization and postoperative care costs, excluding out-of-pocket surgical fees. Consequently, the lower total costs observed for RAH (NTD 65,992 vs. 130,281 for OH and 121,001 for LH) mainly reflect shorter hospital stays, fewer complications, reduced ICU use, and lower transfusion rates. Although robotic surgery generally has higher direct procedural costs, these findings suggest that indirect savings from improved perioperative outcomes may offset upfront expenses in the Taiwanese healthcare context. Recent literature also emphasizes two additional aspects relevant to our findings—cost-effectiveness and technical performance in challenging surgical scenarios. From an economic standpoint, several studies have shown that the introduction of RAH does not necessarily increase the total cost of endometrial cancer management once postoperative recovery and complication rates are considered. Two study demonstrated that while the upfront procedural cost of RAH may be higher, the reduction in transfusion, intensive care use, and length of stay often offsets these expenses, resulting in comparable or even lower overall hospital expenditures [5, 11]. Our national analysis revealed a similar pattern, with RAH showing consistently lower total medical costs across multiple postoperative timeframes, supporting its cost-efficiency within Taiwan’s healthcare reimbursement system. In technically demanding cases, recent studies have underscored RAH’s value in providing enhanced precision and safety. Several studies demonstrated improved outcomes for endometrial cancer patients with complication [17–19]. These findings align with our observation that RAH yields the lowest postoperative complication rate, reinforcing its potential as a preferred approach for complex or high-risk patient populations. Although the RAH group demonstrated lower rates of perioperative complications overall, the slightly higher reoperation and readmission rates observed in our cohort warrant discussion (Table 3). These findings likely reflect the early phase of robotic program implementation in Taiwan, during which complication and reoperation rates are known to decline progressively with increasing surgical experience and program maturation [20]. Additionally, most RAH procedures in our cohort were performed at tertiary referral centers, which typically manage more complex or high-risk patients and maintain stricter postoperative monitoring protocols [21, 22]. Such institutions characteristically maintain lower thresholds for readmission or secondary intervention, leading to higher reported rates despite generally favorable clinical outcomes [23]. Furthermore, minor surgical revisions or short-term readmissions for wound inspection, pain control, or postoperative imaging were more comprehensively documented in the RAH group due to enhanced surveillance practices during program initiation. As robotic surgical experience accumulates and standardization of care pathways continues to advance, these rates are expected to decline, consistent with trends reported in other healthcare systems implementing robotic surgery programs [24]. Claims-based research is inherently constrained by several factors, including potential data incompleteness and inaccuracies in diagnostic coding. To enhance data reliability, we linked EC cases to the Taiwan Cancer Registry (ICD-O-3, C54.1). Nevertheless, information on the initial stage of EC was not fully available. Furthermore, details such as self-financed medications, laboratory results, and patient anthropometrics (e.g., height, weight) were absent due to the limitations of the NHIRD. Measures of disease severity were also unavailable. In addition, because the National Health Insurance Administration requires approximately one year to process and release new datasets, access to the most up-to-date information is delayed. We therefore await the latest data release to perform further in-depth analyses. In conclusion, the introduction of RAH in Taiwan has impacted the clinical approach and outcomes for EC surgery. A retrospective population-based analysis revealed that RAH is associated with several favorable safety outcomes and improved oncological results compared to open hysterectomy. These findings may support increased adoption of RAH in appropriate surgical candidates, especially where feasible and economically justified. Patient numbers represent inverse probability treatment-weighted (IPTW) pseudo-populations to balance baseline covariates across groups.